The Canadian Agency for Drugs and Technologies in Health (CADTH) held consultations, which ended on 14 April 2022, on two new proposals:
- a proposed process for non-sponsored reimbursement reviews; and
- a streamlined process for drug class reviews.
The proposal for non-sponsored reimbursement reviews is intended to apply to scenarios where a sponsor is unwilling or unable to file an application (examples given are drugs approved for small patient populations, drugs nearing the end of their exclusivity (such as patent protection), or drugs not approved by Health Canada for a particular clinical indication but are known to be used in Canadian clinical practice).
The proposal for new streamlined drug class reviews would provide a new streamlined drug class review process that is more efficient and expands CADTH's ability to flexibly deliver evidence and analysis – for example, by creating a process that allows CADTH to leverage existing published evidence where a new meta-analysis or economic analysis is not required.
For further information on this topic please contact Katie Lee at Smart & Biggar by telephone (+1 416 593 5514) or email ([email protected]). The Smart & Biggar website can be accessed at www.smartbiggar.ca.